Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Richardson, Texas

CNS medication trials in Richardson, TX

24 CNS medication studies are recruiting participants at sites in Richardson as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Richardson at a glance

  • 24 studies are recruiting at a site in Richardson.
  • By phase: Phase 1 (3), Phase 2 (9), Phase 3 (12).
  • By sponsor: industry (23), government (1).
  • By research area: Schizophrenia (10), Depression (8), Bipolar Disorder (5), Multiple Sclerosis (1).
  • Most recent update to one of these records: November 13, 2026.

Depression studies recruiting in Richardson

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Seaport Therapeutics
    Study site
    Seaport Investigator Site
    Registry record
    NCT07065240 · updated
  2. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Pillar Clinical Research, LLC
    Registry record
    NCT05850689 · updated
  3. A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Draig Therapeutics Ltd
    Study site
    Draig Clinical Site
    Registry record
    NCT07300969 · updated
  4. Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Vanda Pharmaceuticals
    Study site
    Vanda Investigational Site
    Registry record
    NCT06830044 · updated
  5. Brexanolone Lifting Outcomes Of Moms

    • Phase 3
    • Ages 15 to 45
    • Female participants
    Sponsor
    Lipocine Inc.
    Study site
    Lipocine Investigational Site
    Registry record
    NCT07822321 · updated
  6. A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    AbbVie
    Study site
    Pillar Clinical Research - Richardson /ID# 272821
    Registry record
    NCT06696755 · updated
  7. Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    LB Pharmaceuticals Inc.
    Study site
    Pillar Clinical Research
    Registry record
    NCT07494305 · updated
  8. A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    AbbVie
    Study site
    Pillar Clinical Research - Richardson /ID# 276764
    Registry record
    NCT07276997 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Richardson, TX on ClinicalTrials.gov.

Schizophrenia studies recruiting in Richardson

  1. Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

    • Phase 3
    • Ages 18 to 55
    • All sexes
    Sponsor
    Minerva Neurosciences
    Study site
    Pillar Clinical Research, LLC
    Registry record
    NCT07565428 · updated
  2. A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

    • Phase 1
    • Ages 18 to 60
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Pillar Clinical Research, LLC
    Registry record
    NCT07615426 · updated
  3. Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

    • Phase 2
    • Ages 18 to 60
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT07680946 · updated
  4. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Pillar Clinical Research - Richardson
    Registry record
    NCT07686263 · updated
  5. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT07459647 · updated
  6. A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

    • Phase 1
    • Ages 18 to 55
    • All sexes
    Sponsor
    Leal Therapeutics, Inc
    Study site
    Pillar Clinical Research, LLC
    Registry record
    NCT07734493 · updated
  7. A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    AbbVie
    Study site
    Pillar Clinical Research - Richardson /ID# 275715
    Registry record
    NCT07145918 · updated
  8. 52-week Open Label Safety-Tolerability Study

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    LB Pharmaceuticals Inc.
    Study site
    Pillar Clinical Research
    Registry record
    NCT07369154 · updated
  9. Randomized Withdrawal Study in Patients With Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Vanda Pharmaceuticals
    Study site
    Vanda Investigational Site
    Registry record
    NCT06961968 · updated
  10. Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Reviva Pharmaceuticals
    Study site
    Reviva site
    Registry record
    NCT05184335 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Richardson, TX on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Richardson

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study sites
    Pillar Clinical Research · Pillar Clinical Research - Richardson
    Registry record
    NCT06951711 · updated
  2. A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Pillar Clinical Research - Richardson
    Registry record
    NCT07286175 · updated
  3. A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Pillar Clinical Research - Richardson
    Registry record
    NCT07140913 · updated
  4. A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Pillar Clinical Research - Richardson
    Registry record
    NCT06929273 · updated
  5. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Pillar Clinical Research - Richardson
    Registry record
    NCT06951698 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Richardson, TX on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Richardson

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UT Southwestern Clinical Center at Richardson/Plano
    Registry record
    NCT03816345 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Richardson, TX on ClinicalTrials.gov.

Ask about studies near Richardson

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call